American Journal of HematologyVolume 83, Issue 11 p. 880-881 Correspondence and Letters to the EditorFree Access ESAs: Not a convicted felon but still a suspect Eirini Katodritou, Eirini Katodritou Hematology Department, Theagenion Cancer Center, A. Symeonidi 2, Thessaloniki, GreeceSearch for more papers by this authorEvgenia Verrou, Evgenia Verrou Hematology Department, Theagenion Cancer Center, A. Symeonidi 2, Thessaloniki, GreeceSearch for more papers by this authorKonstantinos Zervas, Konstantinos Zervas Hematology Department, Theagenion Cancer Center, A. Symeonidi 2, Thessaloniki, GreeceSearch for more papers by this author Eirini Katodritou, Eirini Katodritou Hematology Department, Theagenion Cancer Center, A. Symeonidi 2, Thessaloniki, GreeceSearch for more papers by this authorEvgenia Verrou, Evgenia Verrou Hematology Department, Theagenion Cancer Center, A. Symeonidi 2, Thessaloniki, GreeceSearch for more papers by this authorKonstantinos Zervas, Konstantinos Zervas Hematology Department, Theagenion Cancer Center, A. Symeonidi 2, Thessaloniki, GreeceSearch for more papers by this author First published: 08 September 2008 https://doi.org/10.1002/ajh.21282Citations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Ludwig H,Anderson K,Dammaco F, et al. ESAs not the culprit: More studies required. Am J Hematol 10.1002/ajh.21270. 2 Katodritou E,Verrou E,Hadjiaggelidou C, et al. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008; 83: 697– 701. 3 Steensma DP. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. Am J Hematol 2008; 83: 693– 694. 4 Zervas K,Mihou D,Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol 2007; 18: 1369– 1375. 5 Palumbo A,Bringhen S,Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial. Blood, in press. 6 Rajkumar SV,Rosiñol L,Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26: 2171– 2177. 7 Huang J,Li CY,Mesa RA,Wu W,Hanson CA,Pardanani A,Tefferi A. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008; 112: 2726– 2732. 8 Jelkmann W,Bohlius J,Hallek M,Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008; 67: 39– 61. 9 Katodritou E,Terpos E,Zervas K, et al. Hypochromic erythrocytes (%): A reliable marker of recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with multiple myeloma and lymphoma. Ann Hematol 2007; 86: 369– 376. 10 Durie BG,Harousseau JL,Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006; 9: 1467– 1473. Citing Literature Volume83, Issue11November 2008Pages 880-881 ReferencesRelatedInformation